ang iv as group  (MedChemExpress)

Journal: Theranostics

Article Title: Angiotensin IV attenuates diabetic cardiomyopathy via suppressing FoxO1-induced excessive autophagy, apoptosis and fibrosis

doi: 10.7150/thno.48561

Figure Lengend Snippet: The protocol of in vivo experiments and effect of Ang IV on left ventricular function in 5 groups of mice. (A) Animal grouping and timeline of the first part of the in vivo experiment. (B) Animal grouping and timeline of the second part of the in vivo experiment. (C) Representative echocardiographic images in 5 groups of mice. (C1) Two-dimensional echocardiograms showing left ventricular long-axis views, scale bar in mm on the right; (C2) M-mode echocardiograms showing left ventricular dimensions and scale bar in mm on the right, and time stamp in seconds at the bottom; (C3) Pulse-wave Doppler echocardiograms depicting mitral inflow velocities, scale bar in mm/s on the right, and time stamp in seconds at the bottom; (C4) Tissue Doppler echocardiograms displaying mitral annular velocities, scale bar in mm/s on the right, and time stamp in seconds at the bottom. Ang IV: angiotensin IV; AS: FoxO1 inhibitor AS1842856; DM: diabetes mellitus; NC: normal control; STZ: streptozotocin; wks: weeks.

Article Snippet: In the second part, in an attempt to elaborate the roles of AT 4 R and FoxO1 in the effect of Ang IV on diabetic cardiomyopathy, diabetes was induced in 100 mice using the method described above, which were randomly divided into 5 groups (n=20 per group): DM group that received an infusion of vehicle alone, Ang IV group that received an infusion of Ang IV of 2.88 mg/kg/day because high-dose Ang IV showed the best efficacy in the first part of the experiment, Ang IV+divalinal group that received an infusion of Ang IV plus AT 4 R antagonist divalinal (2.88 mg/kg/day, Lintai Biological Technology Company, Xi'an, China), AS group that received an infusion of FoxO1 inhibitor AS1842856 (AS, 20 mg/kg/day, HY-100596, MCE), and Ang IV+AS group that received an infusion of Ang IV plus FoxO1 inhibitor.

Techniques: In Vivo, Control

Journal: Theranostics

Article Title: Angiotensin IV attenuates diabetic cardiomyopathy via suppressing FoxO1-induced excessive autophagy, apoptosis and fibrosis

doi: 10.7150/thno.48561

Figure Lengend Snippet: Effects of AT 4 R and FoxO1 on left ventricular function and expressions of fibrosis-, apoptosis- and autophagy-associated proteins in the myocardium of 5 groups of mice. (A) Representative echocardiographic images in 5 groups of mice. (A1) Two-dimensional echocardiograms showing left ventricular long-axis views and scale bar in mm on the right; (A2) M-mode echocardiograms showing left ventricular dimensions, scale bar in mm on the right, and time stamp in seconds at the bottom; (A3) Pulse-wave Doppler echocardiograms depicting mitral inflow velocities, scale bar in mm/s on the right, and time stamp in seconds at the bottom; (A4) Tissue Doppler echocardiograms displaying mitral annular velocities, scale bar in mm/s on the right, and time stamp in seconds at the bottom. n≥8 per group. (B) Representative Western blot images of Col I, Col III, TGF-β1, Bax, Bcl-2 and Cl-caspase3 protein expressions in the myocardium of 5 groups of mice. (C-G) Quantifications of Col I, Col III, TGF-β1, Bax/Bcl-2 and Cl-caspase3 protein expressions in the myocardium of 5 groups of mice. (H) Representative Western blot images of LC3, Beclin1 and p62 expressions in the myocardium of 5 groups of mice. (I-K) Quantification of LC3-II, Beclin1 and p62 expressions in the myocardium of 5 groups of mice. After DM was successfully induced, mice were divided into the following 5 groups: DM group that received an infusion of vehicle alone, Ang IV group that received an infusion of high-dose Ang IV, Ang IV+divalinal group that received an infusion of high-dose Ang IV plus AT 4 R antagonist divalinal, AS group that received an infusion of FoxO1 inhibitor AS1842856, and Ang IV+AS group that received an infusion of Ang IV plus AS1842856. n=5 per group. Ang IV: angiotensin IV; AS: AS1842856; Cl-caspase3: cleaved caspase 3; Col I: collagen I; Col III: collagen III. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: In the second part, in an attempt to elaborate the roles of AT 4 R and FoxO1 in the effect of Ang IV on diabetic cardiomyopathy, diabetes was induced in 100 mice using the method described above, which were randomly divided into 5 groups (n=20 per group): DM group that received an infusion of vehicle alone, Ang IV group that received an infusion of Ang IV of 2.88 mg/kg/day because high-dose Ang IV showed the best efficacy in the first part of the experiment, Ang IV+divalinal group that received an infusion of Ang IV plus AT 4 R antagonist divalinal (2.88 mg/kg/day, Lintai Biological Technology Company, Xi'an, China), AS group that received an infusion of FoxO1 inhibitor AS1842856 (AS, 20 mg/kg/day, HY-100596, MCE), and Ang IV+AS group that received an infusion of Ang IV plus FoxO1 inhibitor.

Techniques: Western Blot

Journal: Theranostics

Article Title: Angiotensin IV attenuates diabetic cardiomyopathy via suppressing FoxO1-induced excessive autophagy, apoptosis and fibrosis

doi: 10.7150/thno.48561

Figure Lengend Snippet: Effects of AT 4 R and FoxO1 on left ventricular function and dimension in 5 groups of mice of the second part in vivo experiment

Article Snippet: In the second part, in an attempt to elaborate the roles of AT 4 R and FoxO1 in the effect of Ang IV on diabetic cardiomyopathy, diabetes was induced in 100 mice using the method described above, which were randomly divided into 5 groups (n=20 per group): DM group that received an infusion of vehicle alone, Ang IV group that received an infusion of Ang IV of 2.88 mg/kg/day because high-dose Ang IV showed the best efficacy in the first part of the experiment, Ang IV+divalinal group that received an infusion of Ang IV plus AT 4 R antagonist divalinal (2.88 mg/kg/day, Lintai Biological Technology Company, Xi'an, China), AS group that received an infusion of FoxO1 inhibitor AS1842856 (AS, 20 mg/kg/day, HY-100596, MCE), and Ang IV+AS group that received an infusion of Ang IV plus FoxO1 inhibitor.

Techniques: In Vivo

Journal: Theranostics

Article Title: Angiotensin IV attenuates diabetic cardiomyopathy via suppressing FoxO1-induced excessive autophagy, apoptosis and fibrosis

doi: 10.7150/thno.48561

Figure Lengend Snippet: Effects of FoxO1 and AT 4 R on the expressions of fibrosis-, apoptosis- and autophagy-associated proteins in cardiomyocytes. (A) Representative Western blot images of Col I, Col III, TGF-β1, Bax, Bcl-2 and Cl-caspase3 in 7 groups of cells. (B-F) Quantification of Col I, Col III, TGF-β1, Bax/Bcl-2 and Cl-caspase3 expressions in 7 groups of cells. (G) Representative Western blot images of LC3, Beclin1 and p62 in 7 groups of cells. (H-J) Quantification of LC3-II, Beclin1 and p62 expressions in 7 groups of cells. n=3 per group. Ang IV: angiotensin IV; AS: AS1842856; Cl-caspase3: cleaved caspase 3; Col I: collagen I; Col III: collagen III; FoxO1-OE: FoxO1 overexpression. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: In the second part, in an attempt to elaborate the roles of AT 4 R and FoxO1 in the effect of Ang IV on diabetic cardiomyopathy, diabetes was induced in 100 mice using the method described above, which were randomly divided into 5 groups (n=20 per group): DM group that received an infusion of vehicle alone, Ang IV group that received an infusion of Ang IV of 2.88 mg/kg/day because high-dose Ang IV showed the best efficacy in the first part of the experiment, Ang IV+divalinal group that received an infusion of Ang IV plus AT 4 R antagonist divalinal (2.88 mg/kg/day, Lintai Biological Technology Company, Xi'an, China), AS group that received an infusion of FoxO1 inhibitor AS1842856 (AS, 20 mg/kg/day, HY-100596, MCE), and Ang IV+AS group that received an infusion of Ang IV plus FoxO1 inhibitor.

Techniques: Western Blot, Over Expression